Drug Hunter
MAY 21, 2023
This “journal club” article highlights five recent articles of general interest to drug discovery scientists, including reviews on therapeutic areas of interest, principles and areas of medicinal chemistry and pharmacology, and a synthetic transformation worth keeping in mind. 1. A “Magic Chloro” Med. Chem. Review D. Chiodi and Y. Ishihara (Vividion) J.
Drug Discovery Today
MAY 26, 2023
BARCELONA/LONDON, 25.05.23: Seqera Labs, the leading provider of secure workflow orchestration software in the life sciences sector, has partnered with Genomics England, the government-owned company that launched the 100,000 Genomes Project in partnership with the NHS. The new collaboration between Seqera Labs and Genomics England will enable whole genome analysis to be carried out at a larger scale with greater efficiency, helping more patients benefit from genomic healthcare and equipping rese
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Chemical Biology and Drug Design
MAY 25, 2023
PTP1B is a negative insulin signaling pathway regulator; hence, inhibiting PTP1B increases insulin sensitivity, glucose absorption, and energy expenditure. Abstract Diabetes mellitus (DM) is a serious global health concern affecting over 500 million people. To put it simply, it is one of the most dangerous metabolic illnesses. Insulin resistance is the root cause of 90% of all instances of diabetes, all of which are classified as Type 2 DM.
Antidote
MAY 25, 2023
Lupus is a chronic, autoimmune disease that can be extremely difficult to identify and treat. Lupus can occur in anyone , and symptoms can range from mild to life threatening. Consequently, raising awareness and promoting early diagnosis is so important to identify and manage this condition.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Hunter
MAY 22, 2023
We couldn’t include everything in Molecules of the Month, but here’s a round-up of up of 16 additional molecules of potential interest that we didn’t have space for in April, including a highly selective caspase inhibitor from a non-catalytic cysteine, a GPR40 AgoPAM from BMS with activity on GLP-1, a few examples of both on- and off-target toxicities, and several clinical candidates. 1.
Drug Discovery Today
MAY 26, 2023
New branding reflects customer-centric approach and showcases pioneering, single cell analysis technology Rebrand follows a period of significant growth for the Company, including key leadership team appointments, state-of-the-art facility expansion, and new scientific partnerships
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
KIF1A
MAY 24, 2023
What do worms, a classroom full of students, and members of the KAND family community have in common? A lot more than you’d think! In this blog post, KIF1A.ORG Chief Science Officer Dr. Dominique Lessard describes a unique cross disciplinary experience with multiple scientific stakeholders in the rare disease space, all focused around our holistic understanding of KAND.
Drug Hunter
MAY 21, 2023
This article highlights six recent articles of interest in the field of targeted protein degradation including but not limited to potentially new ligases, recruiting motifs, and a discussion on the feasibility of CNS-penetrant degraders. 1. “Reinstating targeted protein degradation with DCAF1 PROTACs in CRBN PROTAC resistant settings” Novartis, Basel, CH + Cambridge, MA BioRxiv , April 14, 2023 This Novartis study identified a novel non-covalent ligand for the E3 ligase receptor DCAF1 for use in
Drug Discovery Today
MAY 25, 2023
The Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines. Transformation of Grade II-listed Victorian waterworks on the River Thames in Hampton, London. Supplying many of the top biopharmaceutical companies in the world to dramatically enhance their ability to develop genetic medicines.Expansion follows recent acceptance of a Drug Master File and first investigational new drug application using doggybone DNA.
Chemical Biology and Drug Design
MAY 21, 2023
Lericiresinol inhibited RA-induced inflammation by maintaining the delicate balance of pro-inflammatory and anti-inflammatory cytokines. It exhibits a strong anti-inflammatory effect against CFA rats via interfering with TGF-α and NF-κB. Abstract Rheumatoid arthritis (RA) is a severe inflammatory auto-immune disorder affecting millions of people across the globe.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Antidote
MAY 22, 2023
Participating in a clinical trial can be a worthwhile opportunity for any individual. Whether taking part as a healthy volunteer or enrolling in a study for a specific condition, being a medical research participant can provide the chance to be more involved in medical treatments, gain access to potential new therapies, and pave the way for medical breakthroughs to take place.
Drug Policy Alliance
MAY 24, 2023
Minnesota Becomes 2nd State to Officially Support Overdose Prevention Centers msutton Wed, 2023-05-24 17:54 Wed, 05/24/2023 - 17:54
KIF1A
MAY 20, 2023
#ScienceSaturday posts share exciting scientific developments and educational resources with the KAND community. Each week, Dr. Dominique Lessard and Dr. Dylan Verden of KIF1A.ORG summarize newly published KIF1A-related research and highlight progress in rare disease research and therapeutic development. KIF1A-Related Research Optogenetic control of kinesins and dynein reveals their specific roles in vesicular transport KIF1A is only one of over 40 kinesin motor proteins in mammals, so why do KI
Chemical Biology and Drug Design
MAY 20, 2023
Compound 2h was identified as the most potent inhibitor of T3SS, which showed strong inhibitory effects on the secretion of the SPI-1 effector proteins in a dose-dependent manner. The compound 2h might affect the SPI-1 genes transcription via impacting the SicA / InvF regulatory pathway. Abstract A series of novel 5-amido-2-carboxypyrazine derivatives were designed, synthesized and evaluated for the inhibitory activities against the T3SS of Salmonella enterica serovar Typhimurium.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Science Daily: Pharmacology News
MAY 25, 2023
There is a massive, mineral-rich region in the Pacific Ocean -- about twice the size of India -- called the Clarion-Clipperton Zone (CCZ), which has already been divided up and assigned to companies for future deep-sea mining. To better understand what may be at risk once companies start mining, a team of biologists has built the first 'CCZ checklist' by compiling all the species records from previous research expeditions to the region.
Drug Channels
MAY 24, 2023
In The Top Pharmacy Benefit Managers of 2022: Market Share and Trends for the Biggest Companies , I shared Drug Channels Institute's analysis showing that three pharmacy benefit managers (PBMs)—the Caremark business of CVS Health, the Express Scripts business of Cigna, and the OptumRx business of UnitedHealth Group—accounted for about 80% of total equivalent prescription claims in 2022.
Drug Patent Watch
MAY 22, 2023
Introducing DrugChatter.com: Empowering Access to Biopharmaceutical Drug Insights through AI Chat We are pleased to introduce DrugChatter.com, a groundbreaking platform that redefines the way professionals obtain concise, cited information on… The post DrugChatter.com: AI Chat for Biopharmaceutical Drug Insights appeared first on DrugPatentWatch - Make Better Decisions.
Broad Institute
MAY 25, 2023
Study finds how a genetic variant raises diabetes risk through an unexpected mechanism By Tom Ulrich May 25, 2023 Breadcrumb Home Study finds how a genetic variant raises diabetes risk through an unexpected mechanism The variant contributes to a unique form of diabetes by reducing fat cells' ability to store fat and respond to insulin By Andrea Tamayo May 25, 2023 Credit: Phil Kubitz, Claussnitzer lab Healthy fat cells, or adipocytes, with numerous fat deposits (green).
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Science Daily: Pharmacology News
MAY 24, 2023
A team of engineers has recently shown that nearly any material can be turned into a device that continuously harvests electricity from humidity in the air. Researchers describe the 'generic Air-gen effect'-- nearly any material can be engineered with nanopores to harvest, cost effective, scalable, interruption-free electricity. The secret lies in being able to pepper the material with nanopores less than 100 nanometers in diameter.
Drug Channels
MAY 23, 2023
In 2022, the PBM market remained highly consolidated—although there were some intriguing share shifts among the largest players. Below, you’ll find Drug Channels Institute's latest estimates of pharmacy benefit manager (PBM) market share based on equivalent prescription claims. I also provide commentary on recent market developments and offer some helpful tips for interpreting the figures.
Drug Target Review
MAY 23, 2023
Inflammatory bowel disease (IBD) is an umbrella term that describes complex disorders that cause chronic inflammation in the digestive tract with alternating periods of relapse and remission. More than 6.8 million people are diagnosed with IBD, which can occur in adults, adolescents and children under the age of 10 and whose quality of life is substantially affected by it.
biobide
MAY 26, 2023
Cancer is a devastating and complex disease, generated by an alteration in the cells, caused by genetic and epigenetic alterations that produce a loss of cell control mechanisms. This transforms the affected cells into uncontrolled entities able to grow limitlessly and disseminate through the organs, damaging them, and causing in the end the irremediable demise of the patient if it is not treated.
Science Daily: Pharmacology News
MAY 25, 2023
New animal research is helping explain why at least five people have become HIV-free after receiving a stem cell transplant, and may bring scientists closer to developing what they hope will be a widespread cure for the virus that causes AIDS. A new study describes how two nonhuman primates were cured of the monkey form of HIV after receiving a stem cell transplant.
Drug Channels
MAY 22, 2023
Dr. Adam J. Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new video webinar: PBMs and the Battle Over Patient Support Funds: Accumulators, Maximizers, and Alternative Funding This event will be broadcast live on Friday, June 23, 2023, from 12:00 p.m. to 1:30 p.m. ET. This page describes the event and explains how to purchase a registration.
Drug Policy Alliance
MAY 25, 2023
Washington, D.C. – Today, the U.S. House of Representatives passed the Halt All Lethal Trafficking of Fentanyl (HALT) Act (H.R. 467) in a 289-133 vote. This legislation would ramp up mandatory minimum sentencing for fentanyl analogues. It would also permanently schedule all fentanyl-related substances as Schedule I without first testing them for benefits or harm.
Drug Target Review
MAY 22, 2023
A recently published study 1 from a large team of cell biologists sheds new light on cellular organisation and variability. Researchers at the Allen Institute for Cell Science , a division of the Allen Institute in Seattle, US, developed a unique mathematical framework to uncover internal organisation of cellular structures in human induced pluripotent stem cells (hiPSCs) while taking account of the wide range of variation that naturally occurs in cell shapes.
Science Daily: Pharmacology News
MAY 24, 2023
Engineers have designed a new class of 'microrobots' several times smaller than the width of a human hair that may be able to treat human illnesses like interstitial cystitis -- a painful bladder disease that affects millions of Americans.
Codon
MAY 22, 2023
Hey! It was a big week in the world of biotechnology. A Bayesian optimization + robotics platform designed and validated enzymes that were more thermostable than their wild counterparts. And experiments at Tune Therapeutics showed that CRISPR epigenome editing — which doesn’t cut DNA at all, but merely silences genes by adding chemical groups to them — can curb “bad cholesterol” by more than 50% in monkeys.
addgene Blog
MAY 23, 2023
You may be familiar with immunofluorescence (IF, often referred to as immunocytochemistry (ICC) when the sample is cultured cells or immunohistochemistry (IHC) with tissues), where an antibody binds a target protein in your sample, then a fluorescently labeled secondary antibody binds that first antibody, then you use a microscope to see where the target protein is (localization) and how much there is (quantification).
The Pharma Data
MAY 26, 2023
Ultomiris approved in Japan for the prevention of relapses in patients with neuromyelitis optica spectrum disorder (NMOSD) Ultomiris (ravulizumab) has been approved in Japan as the first and only long-acting C5 complement inhibitor for the prevention of relapses in patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD), including neuromyelitis optica. 1 The approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) was based on po
Science Daily: Pharmacology News
MAY 24, 2023
Taking a daily multivitamin may help slow age-related memory decline, a new study has found.
Drug Patent Watch
MAY 26, 2023
This chart shows the drugs with the most patents in Slovenia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Slovenia? appeared first on DrugPatentWatch - Make Better Decisions.
Crucial Data Solutions
MAY 26, 2023
If you are working in clinical trials in any capacity, you know the way we do studies has changed dramatically. The post The Power of One Unified and Comprehensive Data Platform for Clinical Trials appeared first on Crucial Data Solutions.
Expert insights. Personalized for you.
144 
Let's personalize your content